The Pericarditis by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pericarditis Market:
https://www.thebusinessresearchcompany.com/report/pericarditis-global-market-report
According to The Business Research Company’s Pericarditis , The pericarditis market size has grown strongly in recent years. It will grow from $2.17 billion in 2023 to $2.35 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of cardiovascular diseases, aging population and higher disease risks, improved understanding of disease pathophysiology, globalization of healthcare, drug development and innovation.
The pericarditis market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increased focus on precision medicine, regulatory support for orphan drugs, patient advocacy and support groups, growing research on inflammatory pathways, global efforts for cardiovascular disease prevention. Major trends in the forecast period include advances in diagnostic technologies, integration of artificial intelligence in diagnostics, management of recurrent pericarditis, telemedicine in follow-up care, patient education and support, enhancements in imaging technologies.
The increasing prevalence of cardiovascular diseases is expected to propel the pericarditis market’s growth going forward. Cardiovascular diseases refer to a term for the conditions affecting the heart or blood vessels. It is usually linked to a buildup of fatty deposits inside the artery and an increased risk of blood clotting. Pericarditis can lead to many cardiovascular diseases or death in extreme cases if it is not treated, so increasing rates of cardiovascular diseases propel the market. For instance, in October 2022, according to an article shared by the Centers for Disease Control and Prevention, a US-based national public health agency, every 40 seconds, a heart attack occurs in the United States. About 805,000 Americans experience a heart attack each year. One in five heart attacks is quiet, the victim is unaware of the damage that has been done. Smoking, high blood pressure, and high cholesterol are major risk factors for heart disease. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the pericarditis devices market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9170&type=smp
The pericarditis market covered in this report is segmented –
1) By Type: Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis
2) By Diagnosis And Treatment: Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (Ct), X-Ray, Medication, Surgical Treatment
3) By Application: Hospitals And Clinics, Medical Institutes, Ambulatory Surgical Centers, Research Organizations
Top Major Players:
- Pfizer Inc.
- AstraZeneca PLC
- Allergan PLC
- Merck & Co. Inc.
- Bayer AG
North America was the largest region in the pericarditis market in 2023.
Major companies operating in the pericarditis market are developing innovative products such as valves for pericardial tissues to meet larger customer bases, more sales, and increase revenue. Valves for pericardial tissue refer to medical devices designed for use in cardiac surgery, particularly in procedures involving heart valve replacement or repair. For instance, in September 2022, Edwards Lifesciences, a US-based technology company, launched the SAPIEN 3 Ultra RESILIA valve. Distinguished by its unique features, the SAPIEN 3 Ultra RESILIA valve integrates Edwards’ groundbreaking RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. Notably, the RESILIA tissue incorporates advanced anti-calcification technology, effectively addressing a key factor contributing to the need for reintervention following heart valve replacement. The SAPIEN 3 Ultra RESILIA valve serves as a prime illustration of Edwards’ ongoing commitment to innovation, aiming to cater to the present and future needs of patients, ultimately enhancing their longevity, health, and overall quality of life.
The pericarditis market report table of contents includes:
1. Executive Summary
2. Pericarditis Market Characteristics
3. Global Pericarditis Market Trends And Strategies
4. Pericarditis Market – Macro Economic Scenario
5. Global Pericarditis Treatment Market Size and Growth
…….
26. Global Pericarditis Market Competitive Benchmarking
27. Global Pericarditis Market Competitive Dashboard
28. Key Mergers and Acquisitions Pericarditis Market
29. Pericarditis Market Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
